Nanoparticle-based inhibition of vascular endothelial growth factor receptors alleviates osteoarthritis pain and cartilage damage
Science Advances · 16.02.2024 · 10 (7)
DOI: 10.1126/sciadv.adi5501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 16.02.2024. Verfasst von Kaige Ma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL 60607, USA. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Osteoarthritis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Osteoarthritis (OA) is characterized by cartilage damage, inflammation, and pain. Vascular endothelial growth factor receptors (VEGFRs) have been associated with OA severity, suggesting that inhibitors targeting these receptors alleviate pain (via VEGFR1) or cartilage degeneration (via VEGFR2). We have developed a nanoparticle-based formulation of pazopanib (Votrient), an FDA-approved anticancer drug that targets both VEGFR1 and VEGFR2 (Nano-PAZII). We demonstrate that a single intraarticular injection of Nano-PAZII can effectively reduce joint pain for a prolonged time without substantial side effects in two different preclinical OA rodent models involving either surgical (upon partial medial meniscectomy) or nonsurgical induction (with monoiodoacetate). The injection of Nano-PAZII blocks VEGFR1 and relieves OA pain by suppressing sensory neuronal ingrowth into the knee synovium and neuronal plasticity in the dorsal root ganglia and spinal cord. Simultaneously, the inhibition of VEGFR2 reduces cartilage degeneration. These findings provide a mechanism-based disease-modifying drug strategy that addresses both pain symptoms and cartilage loss in OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL 60607, USA.
- Department of Chemical Engineering, University of Illinois at Chicago, Chicago, IL 60608, USA.
- Melior Discovery Inc., 869 Springdale Drive 500, Exton, PA 19341, USA.
- Orthopaedic Research Laboratory, Lady Davis Institute for Medical Research, SMBD-Jewish General Hospital, McGill University, Montreal, Canada.
- Department of Anesthesiology, University of Illinois at Chicago, Chicago, IL 60612, USA.
- Jesse Brown Veterans Affairs Medical Center (JBVAMC) at Chicago, IL 60612, USA.
ORCID-Profile: Kaige Ma, Tiep Pham, Jun Wang, InSug O-Sullivan, Shiyu Du, Zeba Farooqui, Gina Votta-Velis, Andre J van Wijnen, Ying Liu, Hee-Jeong Im
Förderung
- NIAMS NIH HHS
Zitieren
APA
Ma, K., Pham, T., Wang, J., O-Sullivan, I., DiCamillo, A., Du, S., Mwale, F., Farooqui, Z., Votta-Velis, G., Bruce, B., van Wijnen, A. J., Liu, Y., & Im, H. J. (2024). Nanoparticle-based inhibition of vascular endothelial growth factor receptors alleviates osteoarthritis pain and cartilage damage. Science Advances, 10(7). https://doi.org/10.1126/sciadv.adi5501
Vancouver
Ma K, Pham T, Wang J, O-Sullivan I, DiCamillo A, Du S, et al. Nanoparticle-based inhibition of vascular endothelial growth factor receptors alleviates osteoarthritis pain and cartilage damage. Science Advances. 2024;10(7). doi:10.1126/sciadv.adi5501
BibTeX
@article{Ma2024,
author = {Ma, Kaige and Pham, Tiep and Wang, Jun and O-Sullivan, InSug and DiCamillo, Amy and Du, Shiyu and Mwale, Fackson and Farooqui, Zeba and Votta-Velis, Gina and Bruce, Benjamin and van Wijnen, Andre J and Liu, Ying and Im, Hee-Jeong},
title = {Nanoparticle-based inhibition of vascular endothelial growth factor receptors alleviates osteoarthritis pain and cartilage damage},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {7},
doi = {10.1126/sciadv.adi5501}
}
EUVIMED